MedTrace Logo

C2Rx Hemofiltration Treatment in Severe or Critically Ill Adults With COVID-19

NCT04537975 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-12-14

No results posted yet for this study

Summary

The clinical trial will evaluate the short term and extended impact on on respiration, pulmonary function and cardiovascular function in C2Rx treatment verse Standard of Care (SOC) in critically ill adults with COVID-19 infections .

Conditions

  • Continuous Renal Replacement Therapy
  • Pulmonary Edema
  • COVID-19

Interventions

DEVICE

C2Rx

Hemofiltration

OTHER

Standard of Care (SOC)

Standard of care that excludes any protocol restrictions.

Sponsors & Collaborators

  • SeaStar Medical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2020-11-15
Completion
2021-01-15
FDA Device
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04537975 on ClinicalTrials.gov